AKTOCYTE: A Revolutionary Nutraceutical for Cancer Care

Recently, in a groundbreaking collaboration, scientists from the Department of Atomic Energy and M/s. IDRS Labs Pvt. Ltd., Bengaluru, have developed AKTOCYTE tablets, aiming to enhance the quality of life for cancer patients undergoing radiotherapy.

Key Points

  • Remarkable Recovery in Pelvic Cancer Patients: AKTOCYTE tablets demonstrate exceptional efficacy in pelvic cancer patients undergoing radiotherapy, leading to significant recovery and eliminating the need for surgical interventions.
  • Versatile Applications: Positioned as an adjuvant to cancer radiotherapy, a regenerative nutraceutical, an immunomodulator, and an antioxidant, AKTOCYTE showcases versatility in addressing various aspects of cancer care.
  • Regulatory Approval: AKTOCYTE received approval from the Food Safety ....
Do You Want to Read More?
Subscribe Now
To get access to detailed content
Buy February 2024 Issue

Already a Member? Login here

Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material before the last six months of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Be an Annual Subscriber

Related Content